{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T22:06:01Z","timestamp":1770933961751,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01426-w","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T08:37:26Z","timestamp":1770885446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of Triple Therapy Containing Encorafenib, Cetuximab, and Binimetinib for BRAF V600E-Mutated Colorectal Cancer: a Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"57","author":[{"given":"Muhammad","family":"Ansab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor Ul Huda","family":"Ramzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghazal","family":"Ishaque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiman","family":"Araib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shree","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farwa","family":"Nisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soban Ali","family":"Qasim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esha","family":"Dilawar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim Halil","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"1426_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/jcm13010040","volume":"13","author":"R Marcellinaro","year":"2024","unstructured":"Marcellinaro R, Spoletini D, Grieco M, Avella P, Cappuccio M, Troiano R, et al. Colorectal cancer: current updates and future perspectives. J Clin Med. 2024;13:40.","journal-title":"J Clin Med"},{"key":"1426_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/nu16010132","volume":"16","author":"Y Liang","year":"2024","unstructured":"Liang Y, Zhang N, Wang M, Liu Y, Ma L, Wang Q, et al. Distributions and trends of the global burden of colorectal cancer attributable to dietary risk factors over the past 30 years. Nutrients. 2024;16:132.","journal-title":"Nutrients"},{"key":"1426_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72:338\u201344.","journal-title":"Gut"},{"key":"1426_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010624","volume":"25","author":"KS Shan","year":"2024","unstructured":"Shan KS, Rehman TU, Ivanov S, Domingo G, Raez LE. Molecular targeting of the BRAF proto-oncogene\/mitogen-activated protein kinase (MAPK) pathway across cancers. Int J Mol Sci. 2024;25:624.","journal-title":"Int J Mol Sci"},{"key":"1426_CR5","unstructured":"Yan W-F, Wu G, Sun P-C, Qiu D. P53 mutations occur more commonly than KRAS mutations in colorectal adenoma."},{"key":"1426_CR6","doi-asserted-by":"publisher","first-page":"100795","DOI":"10.1016\/j.tranon.2020.100795","volume":"13","author":"G Roviello","year":"2020","unstructured":"Roviello G, D\u2019Angelo A, Petrioli R, Roviello F, Cianchi F, Nobili S, et al. Encorafenib, Binimetinib, and cetuximab in BRAF V600E-Mutated colorectal cancer. Transl Oncol. 2020;13:100795.","journal-title":"Transl Oncol"},{"key":"1426_CR7","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R, Cutsem EV, Desai J, Yoshino T, et al. Encorafenib, Binimetinib, and cetuximab in BRAF V600E\u2013Mutated colorectal cancer. N Engl J Med. 2019;381:1632\u201343.","journal-title":"N Engl J Med"},{"key":"1426_CR8","doi-asserted-by":"crossref","unstructured":"Gallois C, Bergen ES, Auclin \u00c9, Pernot S, Higu\u00e9 J, Trouilloud I et al. Efficacy and safety of the combination of encorafenib\/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study. ESMO Open [Internet]. 2024 [cited 2025 Apr 27];9. Available from: https:\/\/www.esmoopen.com\/article\/S2059-7029(24)01465-0\/fulltext","DOI":"10.1016\/j.esmoop.2024.103696"},{"key":"1426_CR9","doi-asserted-by":"crossref","unstructured":"Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D et al. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO Open [Internet]. 2022 [cited 2025 Apr 27];7. Available from: https:\/\/www.esmoopen.com\/article\/S2059-7029(22)00126-0\/fulltext","DOI":"10.1016\/j.esmoop.2022.100506"},{"key":"1426_CR10","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1200\/JCO.22.01693","volume":"41","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, Taieb J, Yaeger R, Yoshino T, Grothey A, Maiello E, et al. ANCHOR CRC: results from a Single-Arm, phase II study of Encorafenib plus binimetinib and cetuximab in previously untreated BRAFV600E-Mutant metastatic colorectal cancer. J Clin Oncol. 2023;41:2628\u201337.","journal-title":"J Clin Oncol"},{"key":"1426_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1426_CR12","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1426_CR13","unstructured":"Ottawa Hospital Research Institute [Internet]. [cited 2025 Apr 27]. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"1426_CR14","unstructured":"Study Quality Assessment Tools | NHLBI. NIH [Internet]. [cited 2025 Apr 27]. Available from: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"key":"1426_CR15","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/sim.1221","volume":"21","author":"B Baujat","year":"2002","unstructured":"Baujat B, Mah\u00e9 C, Pignon J-P, Hill C. A graphical method for exploring heterogeneity in meta-analyses: application to a meta-analysis of 65 trials. Stat Med. 2002;21:2641\u201352.","journal-title":"Stat Med"},{"key":"1426_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/00401706.1988.10488400","volume":"30","author":"RF Galbraith","year":"1988","unstructured":"Galbraith RF. Graphical display of estimates having differing standard errors. Technometrics. 1988;30:271\u201381.","journal-title":"Technometrics"},{"key":"1426_CR17","first-page":"195","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. JBI Evid Implement. 2018;16:195.","journal-title":"JBI Evid Implement"},{"key":"1426_CR18","unstructured":"automeris.io. Computer vision assisted data extraction from charts using WebPlotDigitizer [Internet]. [cited 2025 Apr 27]. Available from: https:\/\/automeris.io\/"},{"key":"1426_CR19","unstructured":"Pandey S. shubhrampandey\/metaSurvival [Internet]. 2024 [cited 2025 Apr 27]. Available from: https:\/\/github.com\/shubhrampandey\/metaSurvival"},{"key":"1426_CR20","first-page":"174","volume":"23","author":"D Kotani","year":"2024","unstructured":"Kotani D, Takashima A, Kato T, Satoh T, Masuishi T, Komatsu Y, et al. Safety and efficacy of Encorafenib, Binimetinib, and cetuximab for BRAFV600E-Mutant metastatic colorectal cancer: results of the Japanese expanded access program. Clin Colorectal Cancer. 2024;23:174\u2013e1826.","journal-title":"Clin Colorectal Cancer"},{"key":"1426_CR21","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1200\/JCO.18.02459","volume":"37","author":"E Van Cutsem","year":"2019","unstructured":"Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle P-J, Elez E, et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E\u2013mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. J Clin Oncol. 2019;37:1460\u20139.","journal-title":"J Clin Oncol"},{"key":"1426_CR22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Andr\u00e9 T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, et al. Combined BRAF, EGFR, and MEK Inhibition in patients with BRAFV600E-Mutant colorectal cancer. Cancer Discov. 2018;8:428\u201343.","journal-title":"Cancer Discov"},{"key":"1426_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.soc.2021.11.006","volume":"31","author":"S Sakata","year":"2022","unstructured":"Sakata S, Larson DW. Targeted therapy for colorectal cancer. Surg Oncol Clin N Am. 2022;31:255\u201364.","journal-title":"Surg Oncol Clin N Am"},{"key":"1426_CR24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","volume":"5","author":"LG Ahronian","year":"2015","unstructured":"Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-Mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 2015;5:358\u201367.","journal-title":"Cancer Discov"},{"key":"1426_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cnur.2016.10.004","volume":"52","author":"JD Tariman","year":"2017","unstructured":"Tariman JD. Changes in cancer treatment: Mabs, Mibs, Mids, Nabs, and Nibs. Nurs Clin North Am. 2017;52:65\u201381.","journal-title":"Nurs Clin North Am"},{"key":"1426_CR26","first-page":"1","volume":"5","author":"Y-H Xie","year":"2020","unstructured":"Xie Y-H, Chen Y-X, Fang J-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020;5:1\u201330.","journal-title":"Signal Transduct Target Ther"},{"key":"1426_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"D-Y Oh","year":"2020","unstructured":"Oh D-Y, Bang Y-J. HER2-targeted therapies \u2014 a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"1426_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd.2018.21","volume":"17","author":"FM Ferguson","year":"2018","unstructured":"Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018;17:353\u201377.","journal-title":"Nat Rev Drug Discov"},{"key":"1426_CR29","doi-asserted-by":"publisher","first-page":"100055","DOI":"10.1016\/j.esmorw.2024.100055","volume":"5","author":"A Fern\u00e1ndez-Montes","year":"2024","unstructured":"Fern\u00e1ndez-Montes A, Ros J, Garc\u00eda-Alfonso P, Gra\u00f1a B, Brozos-V\u00e1zquez E, Meli\u00e1n M, et al. Safety and efficacy of encorafenib\u2013cetuximab combination in BRAFV600E-mutated metastatic colorectal cancer: real-world evidence from the CONFIDENCE Spanish multicenter study. ESMO Real World Data Digit Oncol. 2024;5:100055.","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"1426_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2025.43.4_suppl.16","volume":"43","author":"S Kopetz","year":"2025","unstructured":"Kopetz S, Yoshino T, Van Cutsem E, Eng C, Kim TW, Wasan HS, et al. BREAKWATER: analysis of first-line encorafenib\u2009+\u2009cetuximab\u2009+\u2009chemotherapy in BRAF V600E-mutant metastatic colorectal cancer. J Clin Oncol. 2025;43:16\u201316.","journal-title":"J Clin Oncol"},{"key":"1426_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen Y-J, Ciombor KK, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:329\u201359.","journal-title":"J Natl Compr Canc Netw"},{"key":"1426_CR32","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306\u201315.","journal-title":"Lancet Oncol"},{"key":"1426_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41467-019-14224-9","volume":"11","author":"SA Kennedy","year":"2020","unstructured":"Kennedy SA, Jarboui M-A, Srihari S, Raso C, Bryan K, Dernayka L, et al. Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRASG13D. Nat Commun. 2020;11:499.","journal-title":"Nat Commun"},{"key":"1426_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100\u20133.","journal-title":"Nature"},{"key":"1426_CR35","unstructured":"Triplet-targeted therapy improves survival for patients with advanced colorectal cancer. and BRAF mutations | MD Anderson Cancer Center [Internet]. [cited 2025 Apr 27]. Available from: https:\/\/www.mdanderson.org\/newsroom\/triplet-targeted-therapy-improves-survival-for-patients-with-advanced-colorectal-cancer-and-BRAF-mutations.h00-159304623.html"},{"key":"1426_CR36","doi-asserted-by":"crossref","unstructured":"Kopetz S, Grothey A, Cutsem EV, Yaeger R, Wasan H, Yoshino T et al. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ESMO Open [Internet]. 2022 [cited 2025 Apr 27];7. Available from: https:\/\/www.esmoopen.com\/article\/S2059-7029(22)00095-3\/fulltext","DOI":"10.1016\/j.esmoop.2022.100477"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01426-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01426-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01426-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T21:02:58Z","timestamp":1770930178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01426-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1426"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01426-w","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All authors reviewed and approved the final manuscript and consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"I.H.S. received Advisory Board fees from Pfizer, Seattle Genetics, Guardant Health, GSK, and Lumanity, and was an Invited Speaker for Pfizer and Amgen. All other authors declare no conflicts of interest relevant to the content of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"42"}}